Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • William Blair Acts as Joint Active Bookrunner on BillionToOne’s Initial Public Offering

    William Blair acted as a joint active bookrunner on the $314.0 million initial public offering for BillionToOne, Inc. (Nasdaq: BLLN), a high-growth, commercial-stage precision diagnostics company transforming healthcare through its proprietary single-molecule next-generation sequencing (smNGS) platform.

    Read more

  • Monthly Macro: Pain at the Plug

    Macro analyst Richard de Chazal and group head of energy and power technologies Jed Dorsheimer explore the seismic changes reshaping the U.S. energy landscape as rising electricity costs and surging demand—especially from AI—put unprecedented pressure on the grid. The discussion also unpacks a five‑pillar plan for energy abundance, the balance between renewables and firm baseload power, and the economic and geopolitical forces driving a new era in energy markets.

    Listen to the podcast

  • Economics Weekly: Shutdowns, Tariff Rulings, and Jobs

    In this Economics Weekly, Richard de Chazal discusses the current state of the shutdown and how it could end; what the Trump administration may do next if IEEPA’s use is deemed unjustified; and the latest employment data, given today would have seen the release of the October employment report.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures